

✉ Share this with those who need to know



COVID-19 news from SAMED, Government and Abroad.

DE-ISOLATION RECOMMENDATION FROM THE NDOH

The National Department of Health has suggested de-isolation criteria in line with the guideline for the clinical management of suspected or confirmed COVID-19 disease. This cautious approach adopts recommendations from the WHO.

Download the recommendations [here](#).

[Back to top](#)

COVID-19 DEVELOPMENTS

TRACKING THE PANDEMIC



Gauteng	Western Cape	KwaZulu Natal	Free State	Eastern Cape	Limpopo	Mpumalanga	North West	Northern Cape
136,879	85,772	45,614	10,727	65,316	5,156	7,424	14,337	2,351
Daily Increase								
3,262	-154	2,399	734	2,135	228	295	331	85

Health Minister Dr Zweli Mkhize says that while Gauteng remains at the top in terms of the rate of infections in the country, **KwaZulu-Natal is taking over**. "We are watching and looking at the trends and certainly I think in the country, Gauteng is really at the top of the rate of infection [but] KZN is taking over now," Mkhize said at a visit to Nasrec in Johannesburg on Monday.

As a result, the department was looking at ways of moving forward in KwaZulu-Natal, he said. "KZN is taking over now and therefore we are going to be discussing with them how to move ahead so that they do not get caught up with the numbers."

News24 carries a story of a Durban doctor reporting a case of a COVID-19 **[patient who has been re-infected three months after her initial infection](#)**.

Dr Yuvan Maharaj, who runs a practice in Prospection, said the patient had initially received her positive results on 9 March, a negative test two weeks later, and then a positive result on 14 July. The National Institute of Communicable Diseases (NICD) is now monitoring this patient's case.

"The patient had called me in March suspecting she had picked up the virus as she had returned from a north African country and had started to exhibit flu-like symptoms. "I advised her to have a test done. Two days later, her results came back and she was positive. Fortunately, she was able to self-isolate and I put her on supplements to boost her immunity and treat her symptomatically. After 14 days, she was well and I asked her to go for another test, which came back negative," said Maharaj.

VACCINE DEVELOPMENTS

A cool daily mailer that you can subscribe to, goodmorning@newsweekly.co.za, reports today on the

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

cracked the nod to the Final Phase 3 of human testing. **Oxford's AstraZeneca**, being one such company, published very promising vaccine results yesterday that **rocketed their share price as high as 10%** within a few hours. The vaccine increased levels of both [protective neutralizing antibodies and immune T-cells](#) that target the virus. Although this is still early testing in Phase 3, it is a very important step in the right direction. Making a lot of noise in Phase 2 is America's **Moderna**. They published very promising results which saw their share price boost up over 30%. However, something certainly smells at Moderna HQ as **two execs suddenly sold their shares** after its rise, followed by further reports of the vaccine's side effects being noted. Then finally, to add insult to injury, **JPMorgan** downgraded their Moderna shares due to [valuation concerns](#). Yesterday, the UK became the first country to sign agreements to [purchase 90 million vaccines](#) from three pharmaceutical companies (including that of AstraZeneca as well as Pfizer and Valneva). Although they are not physically buying the vaccines yet, this agreement puts them at the front of the queue when the vaccine gets the green light. Further reading on Britain's pre-order of vaccines is in the [Daily Maverick](#).

[Back to top](#)

COVID-19 EVENTS



LIVE WEBCAST:

22 July 2020 | 2:30 - 3.30 CAT | 3:30 - 4.30 GMT | 4:30 - 5.30 SAT | 5:30 - 6.30 EAT

LEVERAGING ON PARTNERSHIPS : GOVERNMENT AND PRIVATE SECTOR



Moderator
Président,
Association des cliniques
privées de la Côte d'Ivoire



Dr. Eugène Aka Aouélé
Ministre de la santé
et de l'hygiène publique, Côte d'Ivoire



Dr. Jacqueline Lydia Mikolo
Ministre de la Santé et Population
et Ministre de la promotion de la femme.z

(The webinar will have a simultaneous English translation)

REGISTRATION: <https://bit.ly/3haUgPZ>



www.africahf.com



[@AfricaHealthFed](https://twitter.com/AfricaHealthFed)



[Africa Healthcare Federation](#)

[Back to top](#)

UPDATED FORECAST: MPACT OF COVID-19 IN AFRICA

The Hanns Seidel Foundation, the Institute for Security Studies, the Gordon Institute of Business Science, the Frederick S Pardee Centre for International Futures and Humanity United hereby cordially invite you to participate in a joint seminar on **'Updated forecasts: impact of COVID-19 in Africa'**. The speakers will introduce the final version of their much awaited new study, with updated forecasts just generated based on the latest projections released by the IMF.

Date: 23 July 2020

Time: 15:00 to 16:00 GMT+2

Venue: Online via Zoom, [registration](#) required

Enquiries can be sent to Zachel van Aswegen: zvanaswegen@issafrica.org

Download the invitation [here](#).

[Back to top](#)

IHRM: Webinar Update on the Impact of COVID-19

IHRM invites you to join them for a webinar on 31 July at 09h00 when Christoff Raath, Joint CEO of Insight Actuaries and Consultants, will provide an updated analysis on the Impact of COVID-19 on Medical Schemes and Private Hospitals, as South Africa reaches the peak of the pandemic.

For more details or to register [click here](#).

[Back to top](#)

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

[You can update your preferences or unsubscribe from this list.](#)

SAMED is the voice of the South African medical technology industry. The not-for-gain-association was formed in 1985 and aims to provide members with a collective, objective and credible platform to engage with stakeholders. SAMED's members include individual medical technology companies, associate members and associations.

Disclaimer: This e-mail may contain confidential information and may be legally privileged and is intended only for the person to whom it is addressed. If you are not the intended recipient, you are notified that you may not use, distribute or copy this document in any manner whatsoever. Kindly notify the sender immediately and delete the e-mail. The information contained in this mailer is for general information purposes only.

The information is provided by SAMED and whilst SAMED endeavours to ensure that the information is current and correct, it makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability of the information, including graphics, and offerings (collectively referred to as 'information') contained in this mailer for any purpose. Any reliance placed by the user on such information is therefore strictly at the user's own risk. SAMED will not be liable for any loss or damages of whatsoever nature, including without limitation, any direct, indirect, general, special, punitive, incidental or consequential damages, loss of use, loss of data, loss caused by a virus, loss of income or profit, loss of or damage to property and the like, claims of third parties or other losses of any kind or character, arising from or in connection with this mailer and/or accessing any information through links included in or files attached to the mailer.